Gleevec Study for Patients With Ovarian Cancer
NCT00510653
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
73
Enrollment
OTHER
Sponsor class
Conditions
Ovarian Cancer
Interventions
DRUG:
Imatinib Mesylate
Sponsor
M.D. Anderson Cancer Center